OnKure's Upcoming Presentation at a Major Symposium
OnKure Therapeutics, Inc. (NASDAQ: OKUR), a leading player in biopharmaceutical innovations, is eager to share its latest findings at the San Antonio Breast Cancer Symposium (SABCS). This prestigious event, which will take place both virtually and in person, is set to showcase groundbreaking research from December 10 through December 13.
Insights into OKI-219 and PIKture-01 Trial
The spotlight will be on OKI-219, a potential breakthrough in cancer treatment. This selective PI3K?H1047R inhibitor is making waves for its distinctive approach, focusing on mutant-selected solid tumors like breast cancer. Its preliminary clinical data will be discussed in two separate poster sessions, detailing its impressive capabilities to combat these challenging cancers.
First Poster Presentation Highlights
The first poster features early findings from the PIKture-01 trial, a pioneering study examining OKI-219's efficacy in human subjects. The title of this presentation is "Preliminary results from PIKture-01, a First-in-Human Study of OKI-219, a mutant selective inhibitor of PI3K?H1047R, in mutant selected solid tumors including breast cancer." Renowned oncologist Dr. Alexander Spira, alongside his team, will present these findings. This session will be held on December 12, and it promises to reveal vital insights that could reshape treatment strategies.
Second Poster Presentation Insights
The second poster will delve into how OKI-219 synergizes with established standard-of-care therapies in preclinical models. Titled "OKI-219 enhances activity of SOC therapies in double and triple combinations in pre-clinical PI3K?H1047R mutant breast cancer models," this research led by Dr. Molly Taylor and her colleagues will also take place on December 12. The implications of this combination therapy approach could hold extraordinary potential for advancing patient outcomes.
Key Event and Future Plans at SABCS
OnKure's commitment to transparency and collaboration will be further exemplified during a conference call scheduled for December 13. This call will provide stakeholders with an opportunity to discuss the preliminary data from the PIKture-01 trial extensively. Interested parties can dial in to join the conversation and receive updates directly from OnKure's leadership team.
About OnKure and its Vision
OnKure operates at the forefront of biopharmaceutical development, focusing on novel precision medicines aimed at addressing unmet needs in oncology. Their innovative research methodologies, including a structure-based drug design platform, are integral to their advancement in creating targeted therapies. With OKI-219 as the lead program, OnKure is intent on becoming a prominent figure in the oncology landscape, striving to develop best-in-class treatments that pinpoint and mitigate cancerous mutations effectively.
Frequently Asked Questions
What is the main focus of OnKure's research?
OnKure specializes in developing precision medicines that target specific oncogenic drivers in cancers that currently lack effective treatments.
What data will be presented at the SABCS?
OnKure will present preliminary data for OKI-219, including insights from the PIKture-01 clinical trial and its efficacy in combination therapies.
When is the conference call scheduled?
The conference call is scheduled for December 13 to discuss findings from the SABCS presentations.
How can stakeholders access OnKure's presentations?
Stakeholders can follow the conference call or view the presentations through OnKure's website following the event.
What makes OKI-219 notable in cancer treatment?
OKI-219 is recognized as a potential best-in-class treatment that selectively targets specific mutations found in certain cancers, enhancing treatment efficacy.
